Navigation Links
Promising Data Released on New Mesothelioma Therapy
Date:9/30/2015

At the 2015 World Conference on Lung Cancer, Dr. Raffit Hassan of the National Cancer Institute presented promising data on a novel agent, anetumab ravtansine, also known as BAY 94-9343. Anetumab ravtansine is an antibody-drug conjugate directed against the target molecule mesothelin which is highly expressed on mesotheliomas.

This was a phase I study to determine the safety and activity of anetumab ravtansine in patients with cancer who had failed standard therapies. Based on early results of this trial, more mesothelioma patients were enrolled to better define the activity of this drug in patients with pleural mesothelioma who had progressed on chemotherapy. Out of the 16 mesothelioma patients treated at the maximum tolerated dose, 5 (31%) had objective tumor shrinkage while 7 (44%) had stable disease. However, out of the 10 mesothelioma patients who received anetumab ravtansine as second line therapy, 5 (50%) had objective tumor shrinkage and 4 (40%) had stable disease. In most patients, the tumor response was very durable with three patients still receiving the drug more than two years after starting therapy.

“Anetumab ravtansine shows encouraging efficacy in patients with advanced mesothelioma which warrants further study,” stated Dr. Hassan, a senior investigator and the head of the Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute who has been working on developing mesothelin targeted therapies for patients with mesothelioma and other cancers for the last two decades.

Antibody-drug conjugates (also known as ADCs) are a new class of drugs that function by linking a particular antibody to a cancer-fighting drug. When combined, the antibody precisely targets the cancer cell, delivering the drug directly to it, thus avoiding extensive damage to healthy cells typical of traditional chemotherapies.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. With the life expectancy of less than one year after diagnosis, medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards. Currently, few treatment options exist. There is no cure.

About The Mesothelioma Applied Research Foundation
The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer-reviewed scientific research to develop life-saving treatments for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.

###

Read the full story at http://www.prweb.com/releases/2015/10/prweb12991995.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study
2. WesternU and Sight Savers America provide vision-impaired children with a promising future
3. New Mesothelioma Study Calls IMRT/Surgery Combo “Innovative and Promising”, According to Surviving Mesothelioma
4. New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant
5. CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015
6. Neogenis® Labs Named to 2015 Austin A-List Most Promising Startups
7. Recent Research Points to Immunotherapy as Promising New Mesothelioma Approach, According to Surviving Mesothelioma
8. Cendyn/ONE™ named by CIO Review as one of the ‘20 Most Promising Travel & Hospitality Solution Providers’ for 2015
9. Invictus Medical Secures Rights to Second Promising New NICU Technology
10. CIO Review Selects storageFOUNDRY for the 20 Most Promising Storage Solution Providers 2015
11. Kavi Associates has been Awarded the 20 Most Promising SAS Solution Providers 2015 Award by CIO Review - Showcased as a Leader in Business Analytics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2019)... ... August 18, 2019 , ... More Labs ( ... Aqua+, adding two SKUs to its line of functional offerings. Aqua+ is an ... water alone. Distinguishing Aqua+ from other rehydration solutions is the added benefits. On ...
(Date:8/17/2019)... ... August 17, 2019 , ... Inc. ... Private Companies—the Inc. 5000 , For the 2nd Year In a Row, YellowTelescope ... of 192% Percent , Inc. magazine today revealed that YellowTelescope LLC (YellowTelescope, SEOversite, ...
(Date:8/16/2019)... ... August 16, 2019 , ... Cannabinoid Biosciences (“CBDZ”), the Los ... products across the CBD market in the United States in particular and to ... $50 million on September 9, 2019. , Established on May 6, 2014, Cannabinoid ...
(Date:8/16/2019)... ... August 16, 2019 , ... ... custom handcrafted, one-of-a-kind children’s aircraft to Ronald McDonald House Charities in New Hyde ... children residents undergoing medical treatments and their family members a comfortable and fun ...
(Date:8/16/2019)... ... August 16, 2019 , ... Dr. ... joined the esteemed Haute Beauty Network. , The Haute Beauty Network, well known ... Dr. Arnaoutakis as a hair restoration expert and our newest addition to the ...
Breaking Medicine News(10 mins):
(Date:8/19/2019)... ... ... Laurence Fishburne is a revered actor who has many awards under his ... generations. On television, he has also put his skills to use as the host ... gives viewers information in a fair and balanced way. Featuring industry experts on myriad ...
(Date:8/17/2019)... ... August 17, 2019 , ... Inc. Magazine Unveils ... LLC Ranks No. 2502 on the 2019 Inc. 5000 with Three-Year Revenue Growth ... boutique physician recruitment firm is No. 2502 on its annual Inc. 5000 list, ...
(Date:8/16/2019)... ... August 16, 2019 , ... The ... Bend Emergency Physicians (SBEP) of Indiana as a member group. , SBEP is ... South Bend. , SBEP sought out the AAEM-PG for administrative and practice ...
Breaking Medicine Technology: